AZ084是一种具有口服活性的选择性 CCR8 变构拮抗剂,Ki 值为 0.9 nM,可通过下调 Treg 的分化抑制免疫耐受性 PMN 的形成及肿瘤细胞在肺部的转移,可用于研究哮喘和癌症。
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | AZ084 is a potent, selective, allosteric and orally active CCR8 antagonist with a Ki of 0.9 nM [1].AZ084 inhibits the formation of immunologically tolerant pre-metastatic niche (PMN) and metastasis of tumour cells in the lungs through down-regulation of Treg differentiation [1][2].Administered once daily for 4 days at a concentration of 5 μg/mL, AZ084 inhibits the proportion of Treg and reduces CCR8-expressing T cells (cultured ex vivo with LLC-exo MPF CM)[1][2].At concentrations of 0-10 μM, AZ084 inhibited AML, DC and T cells with IC50 values of 1.3 nM, 4.6 nM and 5.7 nM, respectively[2] . |
Animal study | Administered intraperitoneally at a dose of 5 mg/kg every three days for 9 or 21 days, AZ084 inhibited the formation of immunologically tolerant pre-metastatic niche and metastasis of lung tumour cells by down-regulating Treg differentiation[1] .The bioavailability of AZ084 in rats is greater than 70%[2]. |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.30mL 0.46mL 0.23mL |
11.51mL 2.30mL 1.15mL |
23.01mL 4.60mL 2.30mL |
CAS号 | 929300-19-6 |
分子式 | C26H34N4O2 |
分子量 | 434.574 |
别名 | |
运输 | 蓝冰 |
存储条件 |
液体 -20°C:3-6个月-80°C:12个月 粉末 Keep in dark place,Sealed in dry,2-8°C |
溶解度 |
DMSO: 250 mg/mL(575.28 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO |
动物实验配方 |